Protocolo diagnóstico etiológico de las enfermedades metabólicas óseas

  1. Sevilla, J. Escobar
  2. Martín, A. García
  3. Bolívar, V. Contreras
  4. Torres, M. Muñoz
Aldizkaria:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Argitalpen urtea: 2022

Zenbakien izenburua: Enfermedades óseas

Saila: 13

Zenbakia: 60

Orrialdeak: 3565-3571

Mota: Artikulua

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2022.06.015 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado

Laburpena

The skeleton has the double function of maintaining body structure and providing storage for minerals and proteins. The bone that forms the skeleton is a dynamic organ with continuous activity which, in addition, is responsible for maintaining calcium phosphorus homeostasis. It comprises a cellular component (osteoblasts, osteocytes, and osteoclasts) and an extracellular component divided into the extracellular matrix (organic) composed mainly of collagen and an inorganic component formed of hydroxyapatite crystals. The continuous process of bone replacement or turnover (resorption-rest-formation cycle) can be affected at various points; there are various diseases that directly involve the bone. Metabolic bone diseases (MBD) are a heterogeneous group of bone strength disorders generally caused by anomalies in minerals (such as calcium or phosphorus), vitamin D, and/or bone mass or structure. Osteoporosis is the most common MBD. The etiological diagnosis of MBD consists of key points for their proper identification and treatment.

Erreferentzia bibliografikoak

  • Axford JS, O’Callaghan C. Medicine for finals and beyond. CRC Press; 2022.
  • Camacho PM, Petak SM, Binkley N , Diab DL, Eldeiry LS, Farooki A. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26:1-46.
  • Demellawy D, Davila J, Shaw A, Nasr Y. Brief review on metabolic bone disease. Acad Forensic Pathol. 2018; 8(3):611-40.
  • Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, Sugimoto T. Pathogenesis and diagnostic criteria for rickets and osteomalacia - proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society. Endocr J. 2015;62(8):665-71.
  • Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. 2005;19(6):1021-37.
  • Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: synopsis of the kidney disease: Improving global outcomes 2017 clinical practice guideline update. Ann Intern Med. 2018;168(6):422.
  • Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26-36.
  • Landewe R. Principles of assessment from a clinical perspective. Best Pract Res Clin Rheumatol. 2003;17(3):365-79.
  • Reiss E, Alexander F. The tubular reabortion of phosphate in the differential diagnosis of metabolic bone disease. J Clin Endocrinol Metab. 1959;19(10):1212-22.
  • Woolf A. History and physical examination. Best Pract Res Clin Rheumatol. 2003;17(3):381-402.
Datuen iturria: Dialnet